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ABSTRACT
Objectives: Syndromic sexually transmitted infection
(STI) treatment remains a cost-saving HIV prevention
intervention in many countries in Africa. We estimate the
effectiveness of syndromic treatment for curable STIs in
rural KwaZulu-Natal, South Africa, and the trend in STI
prevalences before and after the introduction of
syndromic treatment in 1995.
Methods: Data were available from various clinical
studies, surveys of public and private health providers, the
general population and women attending antenatal, family
planning and child immunisation clinics in rural northern
KwaZulu-Natal between 1987 and 2004. Overall effec-
tiveness was defined as the estimated proportion of the
annual number of symptomatic curable STI episodes
cured by syndromic treatment based on separate
estimates for six curable STI aetiologies by gender.
Results: Median overall effectiveness was 13.1% (95%
CI 8.9 to 17.8%) of symptomatic curable STI episodes
cured. Effectiveness increased to 25.0% (95% CI 17.3 to
33.8%), 47.6% (95% CI 44.5 to 50.8%) or 14.3% (95% CI
9.9 to 19.4%) if 100% treatment seeking, 100% correct
treatment provision or 100% cure were assumed,
respectively. Time-trends were difficult to assess formally
but there was little evidence of decreasing STI
prevalences. Including incurable but treatable herpes
simplex virus (HSV)-2 ulcers in the effectiveness
calculation would halve the proportion of ulcers cured or
correctly treated, but this reduction could be entirely
countered by including episodic antiviral treatment in the
national guidelines.
Conclusion: Overall effectiveness of syndromic treat-
ment for curable STIs in rural KwaZulu-Natal remains low
and there is little evidence of reduced curable STI
prevalences. As syndromic treatment is likely to be a
cost-saving HIV prevention intervention in South Africa,
innovative strategies are urgently needed to increase
rates of treatment seeking and correct treatment
provision.
HIV continues to spread throughout sub-Saharan
Africa.1 Interventions to reduce the transmission of
HIV include behaviour change and reduction of the
per-sex-act transmission probability of HIV.
Among the latter, syndromic case management of
sexually transmitted infections (STIs) is important
and widely implemented, and although the relative
impact of syndromic STI treatment on HIV
incidence is likely to fall over the course of HIV
epidemics,2 it may remain a cost-saving interven-
tion in many countries in sub-Saharan Africa,
particularly those with high HIV incidence.3
South Africa has continuing high rates of STIs
and HIV.4 5 STI treatment services are provided by
the public and private sectors. In the public sector,
syndromic sexually transmitted disease (STD) case
management is recommended based on the 1994
World Health Organization (WHO) guidelines,
adapted and implemented since 1995 by the
South African Department for Health.6 In the
private sector, STI management is at the discretion
of the individual general practitioner (GP).7
Antenatal clinic attendees are also screened and
treated for syphilis.8
We estimate the effectiveness of the syndromic
STI treatment services for curable STIs in rural
KwaZulu-Natal, South Africa, on the basis of
various sources of information and describe the
trend in curable STI prevalences from before the
introduction of syndromic STI management in
1995 until 2004.
METHODS
Data
Unless otherwise noted, data collection was
restricted to the population in the southeast of
Hlabisa sub-district, rural KwaZulu-Natal. The
proportion of STI episodes with recognised clinical
signs (‘‘symptomatic episodes’’) for which treat-
ment was sought among males and females aged
15–49 years old was estimated from primary
analysis of self-reported data collected in a general
population survey in 2003–4 in the southeast part
of the Umkhanyakude district, formerly part of the
Hlabisa sub-district.5 The data presented here are
on individuals whose primary place of residence
was one of the households within the surveillance
area (‘‘residents’’). Consenting adults, who
reported genital ulcers or abnormal genital dis-
charge in the preceding 12 months, were asked
whether they had sought treatment from a doctor
or clinic. Further, the proportion of patients
seeking treatment for STI symptoms for whom
effective treatment was prescribed was estimated
from another surveillance study and two studies of
prescribing patterns of public and private providers
in Hlabisa sub-district in the late 1990s.7 9 10 The
proportion cured among those given appropriate
treatment was measured in a series of clinical
studies carried out in facilities in the Hlabisa sub-
district in 1999/200011 and 2003,12 and Durban in
2000/2001.13 14 The proportions cured were esti-
mated from patients with a single microbiologi-
cally identified and curable aetiology at baseline
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and will reflect both the clinical efficacy of the treatment and
patient adherence.
Data on prevalence of curable STIs were available from
review of data collected in surveys of the general population and
women attending antenatal, family planning and child immu-
nisation clinics in the Hlabisa sub-district between 1987 and
2004.15–21 Syphilis prevalence trend data (diagnosed using rapid
plasma reagin (RPR) only) were available from the Department
of Health.22 Bias in STI prevalence trend data due to sample
differences was limited by restricting data to the populations
listed above.15–21 Data were unadjusted for STI diagnostic
differences.
Effectiveness calculation
The effectiveness of syndromic STI treatment was defined as
Where x is gender, y is syndrome and z is STI aetiology; ax is
the number of residents aged 15–49 years of gender x; bx,y is the
proportion of residents of gender x reporting syndrome y in the
past year; gx,y,z is the proportion of clinic patients of gender x
with syndrome y who are infected with curable aetiology z; dx,y
is the proportion of symptomatic STI episodes for which
treatment was sought for gender x and syndrome y; j is the
proportion of patients seeking treatment who were given
appropriate treatment and kx,z is the proportion cured among
those given appropriate treatment for gender x and STI
aetiology z. The overall effectiveness estimate was based on
separate estimates for six curable STI aetiologies by gender:
Neisseria gonorrhoeae, Chlamydia trachomatis, C trachomatis
(Lympho-granuloma venereum), Trichomonas vaginalis, Treponema
pallidum and Haemophilus ducreyi.
Statistical analysis
Exact 95% CI for all proportions were based on the binomial
distribution. In the effectiveness analysis, uncertainty in all
parameter values was accounted for through specified beta
distributions. Expected median values and 95% CIs for all
derived parameters were calculated using Monte-Carlo sampling
from the beta distributions using WinBUGS version 1.4.1.23
Results were based on 100 000 samples. The distribution
specification and WinBUGS code are shown in the supplemen-
tary material.
Sensitivity analysis
We analysed the robustness of our findings by re-calculating the
effectiveness using alternative assumptions as detailed in full in
the supplementary material.
RESULTS
Altogether, 5424 males and 11 339 females aged 15–49 years old
(44% and 70% of the resident population in these age/sex
groups) participated in a sexual behaviour survey between
January 2003 and August 2004.5 Although there were small
statistically significant differences in some characteristics
between the surveyed and not-surveyed groups, there was little
suggestion of selection bias except that the survey over-sampled
men 15–24 years old (survey = 61%, residents = 54%) and these
men were more likely to have never married. Among individuals
reporting ever having sex, 71% (2547/3587) of males and 69%
(5897/8546) of females provided answers to questions about STI
symptoms in the past year.
Discharge was reported by 6.8% (95% CI 6.1 to 7.6%; n/
N = 299/4372) of males and 14.9% (95% CI 14.2 to 15.7%; 1288/
8617) of females in the preceding year (b, table 1). Ulcers were
reported by 4.3% (95% CI 3.7 to 4.9%; 188/4373) of males and
9.8% (95% CI 9.2 to 10.5%; 851/8,647) of females. Of those for
which treatment seeking data were available and who reported
a single syndrome in the period, 55.9% (95% CI 47.4 to 64.2%;
80/143) of males and 57.1% (95% CI 53.2 to 60.9%; 374/655) of
females reported having sought treatment for discharge and
53.2% (95% CI 38.1 to 67.9%; 25/47) of males and 36.3% (95%
CI 30.7 to 42.2%; 103/284) of females reported having sought
treatment from a doctor or clinic for ulcers (d, table 1).
Using the data sources above, we estimated 2521 sympto-
matic curable STIs in residents of which 52% (1319) were seen
by GPs or at public clinics (h and i, table 1).
All public primary healthcare clinics and 8 of 12 GPs in the
sub-district participated in the clinic-based surveillance study.
Adjusting for the under-representation of GPs, of those seeking
treatment for STI symptoms, 54% (95% CI 51 to 57%; 568/
1052) of the STI episodes were treated in clinics and 46% (95%
CI 43 to 49%; 484/1052) by GPs.7 This study was considered to
be largely representative because all clinics and 67% of GPs
participated. In two further studies of prescribing patterns in
the public and private sectors for patients seeking treatment for
STI syndromes, 41% (95% CI 26 to 57%; 18/44) of patients
attending public clinics10 and 9% (95% CI 2 to 24%; 3/33) of
patients attending their GPs9 received the treatment recom-
mended by the Provincial Health Department. Using these data,
we estimate that 27.4% (95% CI 18.9 to 37.1%) of patients who
sought treatment for STI symptoms from public clinics or GPs
received the correct treatment (j, table 1).
Table 2 shows data on the proportion cured among STI
patients in KwaZulu-Natal treated using the current first-line
treatment regimens from the national syndromic STI treatment
guidelines.6 As the microbiological proportion cured for ulcera-
tive STIs was not available (sampling disrupts epithelialisation),
they were assumed equal to the clinical proportion cured. The
proportion cured for males and females with gonorrhoea was
assumed to be 100% despite increasing resistance to ciproflox-
acin;24 this is in line with the data suggesting that gonorrhoea
remains susceptible to ceftriaxone.25 The proportion cured for
chlamydial and trichomonas infection in women were assumed
to be the weighted mean from the two available studies as these
were not significantly different (87%, 47/54 for C trachomatis;
87%,137/157 for T vaginalis).
Estimated overall effectiveness
Based on these data, effectiveness by gender and aetiology
ranged between 8.6% (95% CI 5.6 to 12.4%) for syphilis ulcers in
females to 15.5% (95% CI 10.6 to 21.2%) for gonorrhoea in
females (table 1). The overall effectiveness of the syndromic STI
treatment services in rural KwaZulu-Natal was estimated to be
13.1% (95% CI 8.9 to 17.8%) of symptomatic curable STI
episodes cured, 14.3% (95% CI 9.8 to 19.5%) for discharge and
9.9% (95% CI 6.6 to 14.0%) for ulcers.
Sensitivity analysis
If 100% treatment seeking was assumed, the estimated overall
effectiveness doubled to 25.0% (95% CI 17.3 to 33.8%). If
100% correct treatment provision was assumed, the overall
Clinical
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effectiveness quadrupled to 47.6% (95% CI 44.5 to 50.8%). If
100% cure was assumed, the overall effectiveness increased
slightly to 14.3% (95% CI 9.9 to 19.4%). If we assumed 10% of
individuals who reported treatment at clinics or GPs actually
went to traditional healers, the overall effectiveness fell slightly
to 11.7% (95% CI 8.1 to 16.0%). If we assumed cure rates were
overestimated by 25%, overall effectiveness decreased to 9.8%
(95% CI 6.7 to 13.4%). If treatment seeking rates were 25%
lower in survey non-participants, overall effectiveness fell
slightly to 11.7% (95% CI 8.0 to 16.0%). Redefining the
effectiveness calculation to include (incurable but treatable)
herpes simplex virus (HSV)-2 ulcers, the overall effectiveness of
syndromic STI treatment for ulcers was halved from 9.9% (95%
CI 6.6 to 14.0%) to 4.1% (95% CI 2.7 to 5.8%). However, if
HSV-2 antiviral treatment was included in the national guide-
lines and 90% of patients adhered, the overall effectiveness
would increase to 9.9% (95% CI 6.7 to 13.9%).
Trend in STI prevalences before and after the introduction of
improved syndromic STI treatment services
The low effectiveness of the syndromic STI treatment services
in rural KwaZulu-Natal estimated above is consistent with the
trends in curable STI prevalences. Table 3 shows the data on
gonorrhoea, chlamydia, trichomoniasis and syphilis prevalence
from surveys of the general population and women attending
antenatal, family planning and child immunisation clinics in
this area. The available data related almost exclusively to
antenatal clinic attendees. The black horizontal line shows the
approximate timing of the introduction of syndromic STI
treatment services in 1995.
The data show very high historic and current STI prevalences.
Between 1987 and 2004, the median prevalences of gonorrhoea,
chlamydia and serological syphilis were 5.8% (range 4.0–10.0%),
10.0% (range 6.4–13.5%) and 8.5% (range 2.0–11.9). The
prevalences of gonorrhoea or chlamydia do not appear to have
fallen since the introduction of syndromic STI treatment.
Serological syphilis prevalence (Treponema pallidum haemagglu-
tination assay (TPHA)+/RPR>1:1) may have fallen since
the introduction of syndromic STI treatment. The median
prevalence of serological syphilis was 11.9% (range 8.5–11.9%)
prior to its introduction and 7.0% (range 2.0–8.5%) since. This fall
in syphilis prevalence in rural northern KwaZulu-Natal is
consistent with the rapid and sustained fall in the RPR titre
among antenatal clinic attendees in the KwaZulu-Natal province,
from 11% in 1997 to around 3% in 2001.22 Data were not available
to explore trends for high-titre active syphilis or trichomoniasis.
DISCUSSION
This study suggests that the syndromic STI treatment services in
rural KwaZulu-Natal cure around 13% of symptomatic curable
STI episodes. This low effectiveness is consistent with the
continuing high prevalence of curable STIs in this population.
Our results suggest that the effectiveness of curable syndromic
STI treatment services could be improved most by increasing rates
of treatment seeking and provision of the correct treatment.
Although our estimates were based on the best available data
and robustly accounted for statistical uncertainty, some caution
is required in the interpretation. Better data on some of the
required parameter values would improve our estimates. For
example, data on the quality of treatment provision were
collected in the late 1990s and provision could have improved or
deteriorated since then, which may lead to an underestimate or
overestimate of effectiveness, respectively. The available data on
STI trends suggest, however, that whatever the trend in overall
effectiveness since the late 1990s, there is no evidence this has
been accompanied by a marked change in STI rates. We had no
information on the total number of syndrome episodes experi-
enced by residents each year, and therefore our estimate of the
annual number of symptomatic episodes in residents is likely to be
a lower bound. We were also required to use cure rate data on
ulcers and urethritis from an urban KwaZulu-Natal population,
which may not a bovne be representative of the study area.
However, the estimate of overall effectiveness was shown to be
robust to increasing the cure rate to 100% and relatively
insensitive to a reduction of 25% in this parameter value—a
range likely to include the true value. Studies to collect more data
on these parameters may be justified and could be used to update
these estimates using the supplied WinBUGS code.
We may have overestimated overall effectiveness for at least
two other reasons. If we overestimated the proportion of
individuals seeking treatment at clinics or their GPs because, for
example, we based our estimate on data from survey
participants rather than all residents, or because patients
actually went to traditional healers, then the overall effectiveness
Table 2 First-line treatment regimens and clinical and microbiological cure rates for national syndromic treatment guidelines by syndrome
Syndrome Treatment regimen
Curable STI
aetiology n
Percentage cured
ReferenceClinical % (n) Microbiological % (n)
Urethritis 500 mg single dose ciprofloxacin since 2001 (250 mg before 2001)
and 200 mg of doxycycline daily for 7 days
NG 135 100 (135) 100 (135) 13
CT 24 100 (24) 83 (20)
Ulcer One intramuscular injection of 2.4 million units of penicillin and 500
mg dose of erythromycin 4 times daily for 5 days.
TP 28 89 (25) 14
No treatment for HSV-2 HD 30 93 (28)
CT (LGV) 29 93 (27)
Vaginal discharge 500 mg single dose ciprofloxacin and 100 mg of
doxycycline 26 daily for 7 days and 2000 mg
metronidazole single dose, or 400 mg metronidazole
26 daily for 7 days
NG 51 65 (33) 80 (41) 11
CT 44 69 (30) 89 (39)
Or if pregnant: one intramuscular injection of 125 mg
ceftriaxone and erythromycin 500 mg 46 daily for
7 days and 400 mg metronidazole 26 daily for 7 days
TV 113 65 (73) 88 (98)
NG 11 100 (11) 12
Or if cervical excitation tenderness: 500 mg single dose
ciprofloxacin and 100 mg of doxycycline 26 daily for
14 days, and 400 mg metronidazole 26 daily for 14 days
CT 10 80 (8)
TV 44 89 (39)
CT, Chlamydia trachomatis; HD, Haemophilus ducreyi; HSV-2, herpes simplex virus type 2; LGV, Lympho-granuloma venereum; NG, Neisseria gonorrhoeae; TP, Treponema pallidum;
TV, Trichomonas vaginalis. Guidelines adapted from.6
H
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would be lower than estimated. Similarly, if the assumed cure
rates were too high because, for example, they were based on data
on patients followed-up rather than those lost to follow-up, then
overall effectiveness would be lower than estimated. However,
this effect was shown to be small and data collected in Tanzania
in the mid-1990s showed little difference between cure rates
among returners and non-returners.26
Conversely, we may have underestimated the overall effec-
tiveness for at least two reasons. We assumed that the cure rate
for incorrect treatment was 0%, but some treatments not in the
national guidelines may be partially effective, increasing the
effectiveness. Also, with the exception of the treatment for
gonorrhoea, only the first-line treatment regimens were
considered. Including the second-line treatment regimens would
have increased effectiveness. However, as the assumed cure
rates were already high, any underestimate will be small.
Our definition of overall effectiveness excluded asymptomatic
STI episodes. This definition was chosen because it can be
considered to be the upper limit for syndromic STI treatment
(barring any indirect treatment via partner notification or cure
of asymptomatic co-infections). However, as a large proportion
of STI episodes are asymptomatic, particularly in women,27 even
if all symptomatic episodes are cured a large proportion of STIs
will remain untreated. This study could be extended to include
asymptomatic episodes, but this would require currently
unavailable aetiology-specific general population data on the
frequency of STI episodes and the proportion of episodes that
became symptomatic.
Our primary aim was to estimate the effectiveness of
syndromic STI treatment services in treating curable STIs.
However, the primary cause of genital ulcers in this population
is HSV-2.14 HSV-2 infection is incurable and antiviral HSV-2
treatment is not recommended in the national guidelines.6 Our
results suggest that if HSV-2 ulcers were included in the
effectiveness calculation the proportion of ulcers cured or
correctly treated was halved, but this reduction could be
entirely countered by including episodic antiviral treatment in
the national guidelines. The lack of treatment for HSV-2 ulcers
may be an important reason for the low treatment seeking rates
in this population, if individuals seeking treatment learn that
treatment is ineffective. If true, then adding episodic HSV-2
antiviral treatment to the syndromic STI treatment guidelines
may have the additional benefit of increasing the treatment
seeking rates for other STIs.
Our STI prevalence trend analysis was limited by changes in
diagnostic methods and sample populations over time and,
therefore, statistical trend-tests were inappropriate. Molecular
diagnostic methods, which have been replacing classical
methods over the period under study, tend to have a higher
sensitivity than classical methods and therefore it is possible
that a decreasing trend in gonorrhoea and chlamydia may have
been obscured. The contrasting fall in syphilis prevalence may
be due, in part, to syphilis treatment of antenatal clinic
attendees.8 Changes in sample populations over time and high
rates of migration and urbanisation in the study area may also
have led to under or overestimation of effectiveness.
A previous study estimated the proportion of women who
were asymptomatic, symptomatic but not seeking care, and
symptomatic and seeking care and infected with T vaginalis,
N gonorrhoeae, C trachomatis or T pallidum on any given day in
Hlabisa health district.28 In line with our findings, the authors
concluded that STIs remained untreated because of low
symptom recognition and treatment seeking rates. Our study
updated this analysis, extended the work to include males,
incorporated other ulcerative STIs, including HSV-2, and
estimated the overall effectiveness of the syndromic STI
treatment algorithm.
Another earlier study estimated the proportion of bacterial
STI cured by primary healthcare services in Mwanza Region,
Tanzania, before and after the introduction of improved STI
treatment services, to be ,10% and 23–41%, respectively.29 The
higher effectiveness estimated for Mwanza than KwaZulu-
Natal was primarily due to higher treatment seeking rates and
higher rates of correct treatment. The higher rates in Tanzania
may have been because community activities were more
intensive as part of an intervention trial, or the division of
STI treatment services between the private and public sectors in
South Africa may make improving services more difficult than
in Tanzania.
Only about 13% of symptomatic STI episodes may be cured
by syndromic STI treatment services in rural KwaZulu-Natal
and there is little evidence to show an improvement in the
prevalence of curable STIs. As long as there is no acceptable
alternative, syndromic STI treatment remains the only option
for the management of STIs in the individual patient. As
syndromic STI treatment may be a cost-saving HIV prevention
strategy in this high HIV-incidence setting,3 innovative strate-
gies are urgently needed to increase rates of treatment seeking
and the provision of the correct treatment.
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